Last reviewed · How we verify
Treatment sequence 1
At a glance
| Generic name | Treatment sequence 1 |
|---|---|
| Sponsor | Janssen Research & Development, LLC |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 and MAS825 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Clonal Hematopoiesis of Indeterminate Potential (CHIP) (PHASE2)
- Pharmacokinetic and Subjective Effects of Heated Tobacco Products (NA)
- Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine (PHASE3)
- Combination Study of SV-BR-1-GM With Retifanlimab (PHASE1, PHASE2)
- A Study to Investigate the Efficacy, Safety, and Tolerability of DFV890 for Inflammatory Marker Reduction in Adult Participants With Coronary Heart Disease and Elevated hsCRP (PHASE2)
- Study in Adult Patients With Moderate to Severe Asthma (PHASE3)
- A Study to Learn How Different Preparations of Osivelotor Taste and Enter the Blood With Food or Liquids or With an Antacid in Healthy Adults (PHASE1)
- Diaphragmatic Physiology Similarity Index May Titrate HFNC Flow Setting: A Prospective Observational Study (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Treatment sequence 1 CI brief — competitive landscape report
- Treatment sequence 1 updates RSS · CI watch RSS
- Janssen Research & Development, LLC portfolio CI